Risk factors associated with postpartum impaired glucose regulation in women with previous gestational diabetes.


Journal

Journal of diabetes and its complications
ISSN: 1873-460X
Titre abrégé: J Diabetes Complications
Pays: United States
ID NLM: 9204583

Informations de publication

Date de publication:
04 2021
Historique:
received: 02 09 2020
revised: 29 12 2020
accepted: 03 01 2021
pubmed: 21 1 2021
medline: 31 12 2021
entrez: 20 1 2021
Statut: ppublish

Résumé

For women with previous gestational diabetes (GDM), international guidelines recommend 75 g oral glucose tolerance test (OGTT) at 4-12 weeks after delivery to assess glucose tolerance, considering their increased risk of type 2 diabetes. We evaluated prevalence of postpartum impaired glucose regulation (IGR) and identified associated risk factors. We retrospectively collected data from 749 women with previous GDM (IADPSG criteria) who underwent postpartum OGTT for type 2 diabetes screening between 2011 and 2019. IGR was identified according to ADA criteria. Prevalence of IGR was 12.7%, lower in women with pre-pregnancy normal weight, higher in women with family history of type 2 diabetes and in those treated with insulin during pregnancy. Prevalence of IGR raised with increasing number of altered glucose values at OGTT performed during pregnancy for GDM screening. HbA1c and triglycerides measured during the third trimester of pregnancy were higher in women with postpartum IGR. At postpartum screening, women with IGR had higher BMI, waist, blood pressure. At multivariate logistic regression analysis, family history of diabetes (OR 2.21; 95% CI: 1.33-3.69; p < 0.01) and presence of all three glucose values exceeding threshold at OGTT during pregnancy (OR 2.89; 95% CI: 1.42-5.86; p < 0.01) were independently associated with IGR. In women with GDM, persistence of IGR in the immediate postpartum period is associated with family history of diabetes and the presence of all three glucose values exceeding diagnostic threshold for GDM at OGTT in pregnancy, suggesting that these women should undergo specific diabetes monitoring and prevention programs.

Identifiants

pubmed: 33468397
pii: S1056-8727(21)00008-8
doi: 10.1016/j.jdiacomp.2021.107854
pii:
doi:

Substances chimiques

Blood Glucose 0
Glucose IY9XDZ35W2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107854

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest No potential conflicts of interest relevant to this article were reported.

Auteurs

Cristina Bianchi (C)

Section of Diabetes, Azienda-Ospedaliero Universitaria Pisana, Pisa, Italy. Electronic address: c.bianchi@ao-pisa.toscana.it.

Giovanni de Gennaro (G)

Section of Diabetes, Department of Clinical & Experimental Medicine, University of Pisa, Pisa, Italy.

Alex Brocchi (A)

Section of Diabetes, Department of Clinical & Experimental Medicine, University of Pisa, Pisa, Italy.

Elisa Minaldi (E)

Section of Diabetes, Department of Clinical & Experimental Medicine, University of Pisa, Pisa, Italy.

Stefano Del Prato (S)

Section of Diabetes, Department of Clinical & Experimental Medicine, University of Pisa, Pisa, Italy.

Alessandra Bertolotto (A)

Section of Diabetes, Azienda-Ospedaliero Universitaria Pisana, Pisa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH